HER2+ metastatic breast cancer in combination with trastuzumab Trastuzumab Aus and and Sept March Sept Kadcyla® 18 Yes 22 None no funding no funding no funding emtansine NZ docetaxel in 2013 2014, 2013 patients listed July who did not 2015 receive prior anti-HER2 treatment or March 2013, Metastatic BRAF May Dec no Vemurafenib Zelboraf® Aus 9 Yes 23 None in no funding no funding positive 2012 2015 registration melanoma with March 2016
Trastuzumab emtansine Kadcyla® Aus and NZ 18 Yes HER2+ metastatic breast cancer in combination with trastuzumab and docetaxel in patients who did not receive prior anti-HER2 treatment or 22 None Sept 2013 March 2014, listed July 2015 no funding Sept 2013 no funding no funding Vemurafenib Zelboraf® Aus 9 Yes Metastatic BRAF positive melanoma 23 None May 2012 March 2013, in with March 2016 no funding Dec 2015 no funding no registration
1-s2.0-S0168851017303457-mmc1.docx